Strimvelis Market Report 2026

Strimvelis Market Overview

• The Strimvelis market growth in the historic period has been driven by advancements in stem cell modification techniques, early success of ada-scid gene therapy trials • Market expansion is supported by expansion of gene therapy commercialization, increasing investments in rare disease pipelines • Growth Driver: Surge In Rare Genetic Disorders Driving Market Growth Due To Rising Demand For Gene Therapy Treatments • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Strimvelis Market?

Strimvelis refers to a gene therapy designed to treat adenosine deaminase deficiency-severe combined immunodeficiency (ADA-SCID). It utilizes a patient’s own stem cells, which are harvested, genetically modified to correct the faulty ADA gene, and then reintroduced into the patient to restore immune function and treat ADA-SCID. The main types of clinical indication in strimveliare are primary indication, patient population, clinical study data, and mechanism of action. The primary indication for Strimvelis is the treatment of Severe Combined Immunodeficiency (SCID) due to Adenosine Deaminase (ADA) deficiency. It is distributed through hospitals and pharmacies and catering to various end users, such as pediatric and adult.

What Is The Strimvelis Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of gene therapy commercialization, increasing investments in rare disease pipelines, growing adoption of personalized medicine approaches, advancements in vector design technologies, rising global access to advanced gene therapies. Major trends in the forecast period include increasing adoption of ex vivo gene therapies, rising focus on personalized genetic treatments, growing utilization of autologous stem cell platforms, expansion of rare disease gene therapy programs, enhanced emphasis on long-term immune reconstitution.

Global Strimvelis Market Segmentation

1) By Clinical Indication: Primary Indication, Patient Population, Clinical Study Data, Mechanism Of Action 2) By Distribution Channel: Hospitals, Pharmacies 3) By End User: Pediatric, Adult

What Are The Drivers Of The Strimvelis Market?

The increase in rare genetic disorders is expected to propel the growth of the strimvelis market going forward. Rare genetic disorders refer to conditions caused by mutations or changes in an individual's DNA and occur infrequently in the general population. The increasing prevalence of genetic disorders can be due to advancements in genetic testing leading to better detection, environmental influences, and, in some cases, lifestyle factors that contribute to mutations in DNA. Strimvelis is a gene therapy that helps rare genetic disorders, particularly adenosine deaminase severe combined immunodeficiency (ADA-SCID), by using the patient's own modified stem cells to introduce a functional copy of the ADA gene, thereby restoring immune function, and offering a potential long-term cure for individuals with this rare, life-threatening condition. For instance, in May 2024, according to the National Health Service, a UK-based government department, in England, approximately 17,000 people live with sickle cell disease, an inherited blood disorder, with around 250 new cases diagnosed each year. Therefore, the increase in rare genetic disorders is driving growth in the strimvelis industry. The rising healthcare expenditure is expected to propel the growth of the strimvelis market going forward. Healthcare expenditure refers to the total amount of money spent on healthcare services and products within a specific time frame, usually measured annually. Rising healthcare expenditure is due to an aging population, increasing prevalence of chronic diseases, advancements in medical technology, higher costs of pharmaceuticals, and the expansion of healthcare access and services. Healthcare expenditure plays a crucial role in supporting therapies such as strimvelis by providing the necessary funding for research, development, accessibility, and administration of innovative treatments, ensuring that patients with rare diseases can receive life-saving interventions. For instance, in April 2025, according to the American Medical Association, a US-based professional medical organization, health spending in the United States increased by 7.5 percent in 2023 to reach 4.9 trillion dollars or 14,570 dollars per capita, marking a notable rise compared with the 4.6 percent growth recorded in 2022. Therefore, the rising healthcare expenditure is driving growth in the strimvelis industry. The growing adoption of personalized medicine is expected to propel the growth of the strimvelis market going forward. Personalized medicine refers to a medical approach that tailors treatment and healthcare strategies to the individual characteristics of each patient. The growing adoption of personalized medicine is due to the increasing availability of precision diagnostic tools, a shift toward value-based healthcare, and the rising demand for more effective and tailored treatment options that improve patient outcomes. Strimvelis helps personalized medicine by providing a targeted gene therapy that is tailored to individual patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID), using their own stem cells to deliver a functional copy of the ADA gene, offering a customized and potentially curative treatment approach based on the patient's unique genetic profile For instance, in February 2024, according to Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the growing adoption of personalized medicine is driving growth in the strimvelis industry.

Key Players In The Global Strimvelis Market

Major companies operating in the strimvelis market are Orchard Therapeutics plc

Regional Insights

North America was the largest region in the strimvelis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Strimvelis Market?

The strimvelis market consists of sales of products including libmeldy, zolgensma, luxturna, roctavian, and skysona. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Strimvelis Market Report 2026?

The strimvelis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the strimvelis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.